{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:29:47Z","timestamp":1787646587174,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cca.2026.120890","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:26:45Z","timestamp":1770654405000},"page":"120890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring synergistic therapeutic potential of Erlotinib and artemisinin in non-small cell lung Cancer (NSCLC) using pharmacological networking and mathematical modeling"],"prefix":"10.1016","volume":"585","author":[{"given":"Faiqa","family":"Suleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasadduq","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah A.","family":"Alshehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz","family":"Muhammad Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghdaa Hamdan","family":"Al Zarzour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.120890_bb0005","article-title":"Current treatments for non-small cell lung cancer","volume":"12","author":"Guo","year":"2022","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.cca.2026.120890_bb0010","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S2213-2600(18)30307-2","article-title":"Erlotinib as adjuvant therapy in <em>EGFR<\/em>\u2212mutant NSCLC","volume":"6","author":"Jassem","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.120890_bb0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4283-z","article-title":"Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial","volume":"18","author":"Mark\u00f3czy","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cca.2026.120890_bb0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2022.08.010","article-title":"Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: a pooled analysis of 438 patients","volume":"172","author":"Wang","year":"2022","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cca.2026.120890_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/012772574X274566231220051254","article-title":"Role of Phytoconstituents in Cancer treatment: a review","volume":"15","author":"Kumar","year":"2024","journal-title":"Recent Adv. Food Nutr. Agric."},{"issue":"1","key":"10.1016\/j.cca.2026.120890_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40199-023-00495-7","article-title":"Co-delivery of artemisinin and metformin via PEGylated niosomal nanoparticles: potential anti-cancer effect in treatment of lung cancer cells","volume":"32","author":"Abdulkareem","year":"2024","journal-title":"DARU J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.cca.2026.120890_bb0035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12032-023-02032-7","article-title":"Enhanced anti-cancer effect of artemisinin-and curcumin-loaded niosomal nanoparticles against human colon cancer cells","volume":"40","author":"Firouzi Amandi","year":"2023","journal-title":"Med. Oncol."},{"issue":"8","key":"10.1016\/j.cca.2026.120890_bb0040","first-page":"1553","article-title":"Dihydroartemisinin enhances sensitivity of nasopharyngeal carcinoma HNE1\/DDP cells to cisplatin-induced apoptosis by promoting ROS production","volume":"44","author":"Cong","year":"2024","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao = J. South. Med. Univ."},{"key":"10.1016\/j.cca.2026.120890_bb0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.leukres.2017.09.022","article-title":"Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells","volume":"62","author":"Tan","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cca.2026.120890_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112157","article-title":"Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer","volume":"133","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cca.2026.120890_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1602581","article-title":"Artemisinin and its derivatives: all-rounders that may prevent the progression from lung injury to lung cancer","volume":"16","author":"Xie","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"13","key":"10.1016\/j.cca.2026.120890_bb0060","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.7150\/jca.57054","article-title":"Artemisinin derivatives inhibit non-small cell lung cancer cells through induction of ROS-dependent apoptosis\/ferroptosis","volume":"12","author":"Zhang","year":"2021","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120890_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/08923973.2016.1267744","article-title":"Artemisinin inhibits inflammatory response via regulating NF-\u03baB and MAPK signaling pathways","volume":"39","author":"Wang","year":"2017","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.cca.2026.120890_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bcp.2018.01.031","article-title":"Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in non-small cell lung Cancer cells harboring EGFR or RAS mutation","volume":"150","author":"Yan","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"13","key":"10.1016\/j.cca.2026.120890_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27134169","article-title":"Application of mathematical modeling and computational tools in the modern drug design and development process","volume":"27","author":"Hasan","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.cca.2026.120890_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jksus.2024.103134","article-title":"Network pharmacology and molecular docking analysis of Catharanthus roseus compounds: implications for non-small cell lung cancer treatment","volume":"36","author":"Alsaif","year":"2024","journal-title":"J. King Saud Univ.-Sci."},{"issue":"10","key":"10.1016\/j.cca.2026.120890_bb0085","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.7150\/ijms.98393","article-title":"Deciphering the anticancer arsenal of Piper longum: network pharmacology and molecular docking unveil phytochemical targets against lung Cancer","volume":"21","author":"Varadharajan","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.cca.2026.120890_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156265","article-title":"The role of IL-17 in lung cancer growth","volume":"169","author":"Liu","year":"2023","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.cca.2026.120890_bb0095","doi-asserted-by":"crossref","DOI":"10.31083\/j.fbl2812357","article-title":"Cellular senescence in non-small cell lung cancer","volume":"28","author":"Zhu","year":"2023","journal-title":"Front. Biosci. Landmark"},{"issue":"1","key":"10.1016\/j.cca.2026.120890_bb0100","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41418-019-0352-3","article-title":"Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis","volume":"27","author":"Chen","year":"2020","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.cca.2026.120890_bb0105","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jtho.2021.04.003","article-title":"Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?","volume":"16","author":"Qiao","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.cca.2026.120890_bb0110","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.molcel.2019.08.028","article-title":"Metabolic diversity in human non-small cell lung cancer cells","volume":"76","author":"Chen","year":"2019","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.cca.2026.120890_bb0115","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.cca.2026.120890_bb0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","article-title":"Evaluation of drug combination effect using a bliss independence dose\u2013response surface model","volume":"10","author":"Liu","year":"2018","journal-title":"Stat. Biopharm. Res."},{"key":"10.1016\/j.cca.2026.120890_bb0125","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3389\/fphar.2019.01384","article-title":"Additive dose response models: defining synergy","volume":"10","author":"Lederer","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cca.2026.120890_bb0130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126000720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126000720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:59:47Z","timestamp":1787644787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126000720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S0009898126000720"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.120890","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring synergistic therapeutic potential of Erlotinib and artemisinin in non-small cell lung Cancer (NSCLC) using pharmacological networking and mathematical modeling","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.120890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120890"}}